Spearheading Immunotherapies

Harpoon is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases.

At the heart of Harpoon’s approach is a novel antibody-derived platform called TriTAC™ (Tri-specific T cell Activating Construct) designed for targeted penetration and destruction of solid tumors and hematologic malignancies, and engineered to bind to human serum albumin for improved therapeutic schedule and patient convenience.

Management Team

Board of Directors


Scientific Advisory Board


Our Partners

In October 2017, Harpoon entered into an immuno-oncology research collaboration with AbbVie to advance next-generation cancer immunotherapies. The goal of this ongoing collaboration is to combine the strength of Harpoon’s TriTAC™ platform and development technology with AbbVie’s T cell receptor (TCR) targets to develop candidates against novel targets. Harpoon is responsible for conducting certain research and discovery activities under a mutually agreed research plan to create and evaluate proprietary TriTACs™ directed at the agreed upon targets of interest.